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Essentials
• RAS proteins are expressed in platelets but their func-
tions are largely uncharacterized.
• TC21/RRas2 is required for glycoprotein VI-induced
platelet responses and for thrombus stability in vivo.
• TC21 regulates platelet aggregation by control of aIIbb3
integrin activation, via crosstalk with Rap1b.
• This is the first indication of functional importance of a
proto-oncogenic RAS protein in platelets.
Summary. Background: Many RAS family small GTPases
are expressed in platelets, including RAC, RHOA, RAP,
and HRAS/NRAS/RRAS1, but most of their signaling
and cellular functions remain poorly understood. Like
RRAS1, TC21/RRAS2 reverses HRAS-induced suppres-
sion of integrin activation in CHO cells. However, a role
for TC21 in platelets has not been explored. Objectives:
To determine TC21 expression in platelets, TC21 activa-
tion in response to platelet agonists, and roles of TC21 in
platelet function in in vitro and in vivo thrombo-
sis. Results: We demonstrate that TC21 is expressed in
human and murine platelets, and is activated in response
to agonists for the glycoprotein (GP) VI–FcRc
immunoreceptor tyrosine-based activation motif (ITAM)-
containing collagen receptor, in an Src-dependent man-
ner. GPVI-induced platelet aggregation, integrin aIIbb3
activation, and a-granule and dense granule secretion, as
well as phosphorylation of Syk, phospholipase Cc2,
AKT, and extracellular signal-regulated kinase, were
inhibited in TC21-deficient platelets ex vivo. In contrast,
these responses were normal in TC21-deficient platelets
following stimulation with P2Y, protease-activated recep-
tor 4 and C-type lectin receptor 2 receptor agonists,
indicating that the function of TC21 in platelets is GPVI–
FcRc-ITAM-specific. TC21 was required for GPVI-
induced activation of Rap1b. TC21-deficient mice did not
show a significant delay in injury-induced thrombosis as
compared with wild-type controls; however, thrombi were
unstable. Hemostatic responses showed similar
effects. Conclusions: TC21 is essential for GPVI–FcRc-
mediated platelet activation and for thrombus stability
in vivo via control of Rap1b and integrins.
Keywords: blood platelets; collagen receptors; embolism
and thrombosis; monomeric GTP-binding proteins; RAS
proteins.
Introduction
Platelets rely on fast, highly coordinated cytosolic signal
transduction to mediate rapid responses to prothrombotic
stimuli. These ‘inside-out’ signaling responses lead to acti-
vation of allbb3 integrin adhesion receptors, which bind
fibrinogen, allowing platelets to maintain hemostasis in
response to vascular injury on a time scale of seconds to
minutes [1]. The RAS family small GTPase Rap1b is a
proximal player in integrin activation by recruiting talin
[2–9]. Many pathways of Rap1b activation in platelets
have been studied; however, the molecular basis of plate-
let activation remains incompletely understood. Previous
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studies have shown that other RAS small GTPases may
have some functions in platelets, but the RAS isotypes
involved in platelet functional responses were not identi-
fied [10,11]. Much of the knowledge regarding RAS small
GTPases and integrins comes from overexpression stud-
ies. HRAS was found to suppress activation of chimeric,
ectopically expressed integrins in CHO cells, whereas
RRAS1 and RRAS2/TC21 can reverse suppression by
HRAS [7,8,12,13]. Proteomic analysis of palmitoylated
proteins demonstrated moderate expression of several
RAS isotypes in platelets, including HRAS, NRAS, and
RRAS1 [14].
RRAS2, also known as TC21 and encoded by the
RRAS2 gene, shares features with both oncogenic RAS
and RRAS subgroups. RRAS2/TC21 can stimulate the
RAL, phosphoinositide 3-kinase (PI3K) and RAF–MEK–
extracellular signal-regulated kinase (ERK) pathways, and
is strongly tumorigenic; also, somatic mutations that make
it insensitive to inactivation by GAPs are prevalent in
many human tumors. TC21 also regulates cell migration
and survival; these functions resemble those of RRAS1
[15–19]. TC21, like RRAS1, can also reverse the suppres-
sion of activation of chimeric integrins by HRAS [13].
Rras2/ mice are lymphopenic, owing to poor survival
and homeostatic proliferation of peripheral T and B cells,
reflecting a TC21-dependent T-cell receptor (TCR) recy-
cling mechanism: TC21 constitutively associates with the
TCR and B-cell receptor (BCR) immunoreceptor tyro-
sine-based activation motif (ITAM) and recruits PI3K to
these sites, which is required for its activation [20,21].
Despite these defects, Rras2/ knockout mice appear
grossly normal (viable and fertile), but have a delay in
mammary gland development, owing to a reduction in
terminal end buds and ductal branching [20]. We have
found that TC21 is highly expressed in murine and
human platelets. In this study, we investigated roles for




2MeSADP, sodium citrate, fucoidan, acetylsalicylic acid,
apyrase (type VII) and bovine serum albumin (fraction V)
were from Sigma (St. Louis, MO, USA). AYPGKF was
custom-synthesized by Invitrogen (Carlsbad, CA, USA).
Collagen-related peptide (CRP) was from R. Farndale at
the University of Cambridge. Convulxin was purified as
described previously [22]. Type I collagen was from
Chrono-log (Havertown, PA, USA). Phycoerythrin-conju-
gated JON/A antibodies, fluorescein isothiocyanate
(FITC)-conjugated anti-P-selectin antibodies and FITC-
conjugated anti-glycoprotein (GP) VI antibodies were
from Emfret Analytics (Wurzburg, Germany). Mouse
anti-TC21 antibodies were from Abnova (Walnut, CA,
USA). 2,3-Dihydro-3-[(1-methyl-1H-indol-3-yl) methy-
lene]-2-oxo-1H-indole-5-sulfonamide (OXSI-2) was from
Tocris Biosciences (Minneapolis, MN, USA). IV.3
(CD32) antibodies were from Stemcell Technologies
(Cambridge, MA, USA), and goat anti-mouse IgG
(Fab02) antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). FcRc antibodies were from
Sigma (St Louis, MO, USA). Anti-phospho-Syk (Tyr525/
Tyr526), anti-phospho-phospholipase Cc2 (PLCc2)
(Tyr759), anti-phospho-AKT (Ser473), anti-phospho-
ERK (Thr202/Tyr204) and anti-b-actin antibodies were
from Cell Signaling Technology (Beverly, MA, USA).
PP2 and PP3 were from Enzo Life Sciences (Farmingdale,
NY, USA). Human fibrinogen was from Enzyme
Research Laboratories (Enzo Life Sciences, Farmingdale,
NY, USA). PPACK (Enzo Life Sciences) was from Gly-
cotech (Gaithersburg, MD, USA). RAF-1 and RALGDS
glutathione-S-transferase (GST)–RBD proteins were pre-
pared as described previously [23,24]. All other reagents
were reagent-grade, and deionized water was used
throughout.
Animals
Rras2/ mice were a gift from B. Alarcon, Universidad
Autonoma de Madrid, Madrid, Spain. These mice were
backcrossed 10 times against a C57Bl/6 background.
Wild-type (WT) C57Bl/6 mice were from Charles River
Laboratories (Wilmington, MA, USA). All mice were
housed in a pathogen-free facility, and all animal proce-
dures were approved by the Temple University Institu-
tional Animal Care and Use Committee. Age-matched
and gender-matched WT mice were used as controls.
Preparation of human and murine platelets
Human and murine platelets were isolated from blood as
described previously [25]. Approval was obtained from
the Institutional Review Board of Temple University.
Informed consent was provided prior to blood donation,
in accordance with the Declaration of Helsinki.
Platelet aggregation and secretion
Platelet ATP release and aggregation were performed
simultaneously with a lumi-aggregometer, as described
previously [25].
Flow cytometry
Washed murine platelets were labeled with phycoerythrin-
conjugated JON/A antibodies or FITC-conjugated anti-P-
selectin antibodies, and detected as described previously
[26].
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Western blotting
Platelets were stimulated with agonists for the appropriate
time, and protein levels and phosphorylation events were
assessed as described previously [27].
GTP–TC21 and GTP–Rap1b pulldown assays
Washed platelets (0.5 mL, 2 9 109 mL1) were stimulated
with different agonists in an aggregometer, and reactions
were stopped by the addition of 250 lL of 3 9 HEPES
lysis buffer (55 mM HEPES, 174 mM NaCl, 30% glycerol,
6 mM EGTA, 6 mM MgCl2, 3% NP40, pH 7.5) with
10 lM GTP and 20 lg GST–RBD of RAF-1 or
RALGDS [23,24]. Platelet lysates were clarified by cen-
trifugation at 13 000 9 g for 5 min at 4 °C. Fifty-microli-
ter supernatants were separated for whole cell lysate
samples, and 40 lL of glutathione–agarose beads were
added to the remaining supernatant and kept on a rocker
for 2 h at 4 °C. Bead-bound complexes were washed
three times with 1 9 HEPES wash containing 10 lM
GTP, eluted with SDS sample buffer, and analyzed by
western blotting.
Immunofluorescence microscopy
These experiments were performed as described previ-
ously [28,29].
Platelet spreading and clot retraction
These experiments were performed as described previ-
ously [25].
FeCl3-induced in vivo thrombosis and bleeding times
Adult mice (aged 10–12 weeks) were anesthetized by
intraperitoneal injection of pentobarbital (40 mg kg1),
and FeCl3-induced thrombosis was assessed as described
previously [30]. Bleeding times following tail clip were
assessed in 6–8-week-old male and female mice, as
described previously [30].
Blood flow over collagen
Blood was collected from 12–14-week-old mice via car-
diac puncture into tubes containing 400 mM PPACK
and 5 U mL1 heparin as anticoagulant. Blood was
passed over surfaces coated with 50 lg mL1 type I col-
lagen at 500 s1 for 3 min by use of a parallel-plate flow
chamber kit from Glycotech. The chamber was flushed
with phosphate-buffered saline, and images were
obtained with a Nikon Eclipse TE300 at 9 400 magnifi-
cation (Nikon, Melville, NY, USA). Thrombus area was
quantified with IMAGEJ. At least five randomly chosen
images were used for analysis per experiment.
Statistical analysis
Each experiment was performed at least three times
unless otherwise indicated. All statistical tests were carried
out using PRISM software (version 3.0). Data are presented
as means + standard error of the mean. Statistical signifi-
cance was determined with Student’s t-test and ANOVA.
Results
Expression of the small GTPase TC21 in platelets and
involvement in GPVI-induced platelet functional responses
Early studies showed that ‘RAS’ (isotype not specified) can
be activated in platelets, and RAS proteins appear to be
important for platelet functions [10,11,31]. RRAS1 is also
expressed in human platelets [14], but its functions are
unclear. Western blot analysis with TC21 mouse mAbs
confirmed the findings of prior proteomic studies [32], and
demonstrated that TC21 is expressed in both human and
murine platelets, at levels similar to those in peripheral
blood mononuclear cells, in which TC21 plays important
functional roles [21,33,34] (Fig. 1A). There are currently
no selective pharmacological inhibitors of TC21. To evalu-
ate the functions of TC21 in platelets, we investigated ago-
nist-induced platelet responses ex vivo in platelets isolated
from TC21-null (Rras2/) mice [21]. TC21 is expressed in
WT murine platelets but not in TC21-null murine platelets
(Fig. 1B). TC21-null mice had decreased circulating plate-
let counts relative to WT mice, indicating potential defects
in either platelet production or platelet lifespan; however,
mean platelet volumes were in the normal range (Fig. 1C).
Ex vivo platelet aggregation and dense granule secretion
induced by the GPVI-specific agonists CRP and convulxin
were inhibited in TC21-null platelets as compared with WT
platelets (Fig. 2A). These defects were reversed with higher
concentrations of CRP, suggesting compensatory mecha-
nisms in the absence of TC21 with higher doses of agonist.
Similarly, collagen-induced aggregation and dense granule
secretion were inhibited with low concentrations of agonist
(0.5–0.75 lg mL1), but not at higher concentrations
(Fig. 2B). However, platelet aggregation and secretion in
response to the protease-activated receptor (PAR) 4-acti-
vating peptide AYPGKF or P2Y receptor agonist
2MeSADP were similar in TC21-null and WT platelets
(Fig. 2C), indicating that G-protein-coupled receptor ago-
nists induce normal platelet aggregation and secretion in
the absence of TC21. Thus, TC21 is required for platelet
aggregation and dense granule secretion downstream of
GPVI receptor pathways.
TC21 regulates platelet GPVI-mediated integrin activation
and a-granule secretion
Platelet aggregation results from the activation of integrin
aIIbb3, mediated by inside-out signaling downstream of
© 2018 International Society on Thrombosis and Haemostasis
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ligation of signaling receptors [1]. We analyzed the ago-
nist-induced activation of integrin aIIbb3 by measuring
binding of the conformation-dependent antibody JON/A
to stimulated platelets by using flow cytometry [35]. Con-
sistent with a defect in GPVI-mediated platelet aggrega-
tion, we found that JON/A binding induced by different
concentrations of CRP and convulxin was significantly
inhibited in TC21-null platelets as compared with WT
platelets (Fig. 3A). Thus, TC21 is required for GPVI-
mediated inside-out signaling leading to integrin activa-
tion and platelet aggregation. P-selectin surface expression
induced by CRP and convulxin was also significantly
blocked in TC21-null platelets (Fig. 3B), indicating
defects in a-granule secretion [36]. However, at both low
and high concentrations, AYPGKF-induced and
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Fig. 1. Expression of TC21/RRas2 in human and murine platelets. (A) Whole cell lysates (WCLs) of washed human (2 9 108 mL1) and mur-
ine (1.5 9 108 mL1) platelets and peripheral blood mononuclear cells (PBMCs) were separated by SDS-PAGE and immunoblotted with TC21
antibodies. Hemavet analysis showed no detectable levels of leukocytes or erythrocytes. (B) Western blots of WCL samples from wild-type (WT)
and TC21-null (TC21 knockout [KO]) C57Bl/6 mouse platelets, with TC21 antibodies. Hemavet analysis showed no detectable levels of
leukocytes or erythrocytes. (C) Platelet counts in plasma (left) and mean platelet volume (right) were assessed by Hemavet analysis. n = 6.
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CRP 2.5 µg mL–1
Collagen 2 µg mL–1
AYPGKF 75 µmol L–1 AYPGKF 100 µmol L–1 2MeSADP 10 nmol L–1 2MeSADP 25 nmol L–1
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WT TC21 KO WT TC21 KO WT TC21 KO WT TC21 KO
TC21 KO TC21 KOWT WT TC21 KOWT
CRP 5 µg mL–1 CRP 10 µg mL–1 Convulxin 75 nmol L–1A
B
C
Fig. 2. TC21 is required for glycoprotein VI-induced platelet aggregation and dense granule secretion. TC21-null (TC21 knockout [KO]) and
wild-type (WT) murine platelets isolated from whole blood were resuspended in phosphate buffer and apyrase at physiological pH, placed
under stirring conditions in a lumi-aggregometer in the presence of luciferin–luciferase reagent, and then stimulated with collagen-related pep-
tide (CRP) (2.5, 5 and 10 lg mL1) and convulxin (75 nM) (A), collagen (0.5, 0.75, 1 and 2 lg mL1) (B) or AYPGKF (75 and 100 lM) and
2MeSADP (25 nM) (C) for 3.5 min. Representative aggregation (top) and dense granule secretion (bottom) tracings from three independent
experiments are shown.
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expression in TC21-null platelets were similar to those in
WT platelets (Fig. 3C,D), indicating that G-protein-
coupled receptor agonists cause integrin aIIbb3 activation
and a-granule secretion independently of TC21. Surface
expression levels of integrin aIIbb3 and GPVI in TC21-














































































































































Fig. 3. TC21 is required for glycoprotein (GP) VI-induced platelet aIIbb3 integrin activation and a-granule secretion. (A–D) Washed platelets from
TC21-null (knockout [KO]) and wild-type (WT) murine platelets were stimulated with the indicated doses of collagen-related peptide (CRP) or
convulxin (A, B), or AYPGKF or 2MeSADP (C, D) for 15 min in the presence of phycoerythrin-labeled JON/A antibodies (A, C) or fluorescein
isothiocyanate-labeled anti-P-selectin antibodies (CD62) (B, D), and labeling was assessed by flow cytometry. Mean fluorescence intensities (MFIs)
are shown as fold change from unstimulated (US) control, and are representative data from three independent experiments, + standard error of the
mean. *P < 0.05. (E, F) Washed platelets were labeled with antibodies against GPVI (E) or aIIb integrin (F), and fluorescence intensities were
detected by fluorescence-activated cell sorting. (G) Washed platelets from TC21-null and WT mice were either kept US or treated with
2.5 lg mL1 CRP for 60 s, lysed, and subjected to immunoprecipitation (IP) with anti-GPVI antibodies. IP fractions were separated by SDS-
PAGE and western blotting with the indicated antibodies. The FcRc band migrated at ~ 14 kDa. NS, not significant; WCL, whole cell lysate.
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(Fig. 3E, F). Expression of FcRc was also similar to that
in WT platelets, and FcRc phosphorylation in response
to platelet stimulation with CRP was also similar to that
in WT platelets (Fig. 3G). Thus, TC21 is selectively
required for GPVI-mediated activation of aIIbb3 integrin,
dense granule and a-granule secretion, and aggregation
responses in platelets.
Inhibition of GPVI-mediated downstream signaling events in
platelets in the absence of TC21
Many signaling players in the GPVI integrin activation
pathway have been investigated in platelets [37,38]. To
determine whether TC21 regulates these signaling events,
we assessed GPVI-mediated signaling in lysates of TC21-
null or WT platelets stimulated with GPVI agonists, by
immunoblotting with phospho-specific antibodies: anti-
Syk (Y525/526), anti-PLCc2 (Y759), anti-AKT (S473),
and anti-ERK1/2 (T202/Y204). CRP treatment of WT
platelets at 2.5 lg mL1 caused a rapid signaling
response, including phosphorylation of each of these tar-
gets. In contrast, CRP-induced phosphorylation of Syk,
PLCc2, AKT and ERK1/2 was reduced in TC21-null pla-
telets (Fig. 4A). Similar results were observed with CRP
stimulation at 5 lg mL1, with repression of GPVI sig-
naling responses in TC21-null platelets. However, with
CRP stimulation at 10 lg mL1, GPVI signaling
responses were similar in TC21-null and WT platelets
(Fig. 4A). When platelets from TC21-null mice were stim-
ulated with AYPGKF or 2MeSADP, phosphorylation
levels of AKT and ERK were comparable to those in
WT platelets (Fig. 4B). These results demonstrate that
TC21 regulates GPVI downstream signaling responses,
and suggest a receptor-proximal role, upstream of Syk,
for TC21 in GPVI-mediated signaling phosphorylation
events.
TC21 activation induced by GPVI receptor agonists requires
Src family kinases (SFKs)
The above results demonstrate a requirement for TC21
expression in GPVI signaling in platelets, and suggest that
the molecular function of TC21 may be an important fac-
tor in these responses. Therefore, we assessed TC21 acti-
vation in human platelets following GPVI agonist
stimulation, by using a standard pulldown assay for
GTP-bound RAS proteins, employing the RAS-binding
domain of RAF-1 fused to GST (GST–RBD) as bait
bound to glutathione–sepharose beads [23]. This GST
fusion protein is predicted to bind to activated, GTP-
bound TC21 [15,19], such that immunoblotting of the
precipitated fractions indicates a ratio of activated TC21
and total TC21 from the whole platelet lysate. TC21 was
precipitated by GST–RBD in lysates from human plate-
lets stimulated with CRP and convulxin (GPVI agonists),
but not in those from unstimulated platelets, confirming
the utility of this approach for assessing TC21 cellular
activation in platelets. CRP and convulxin – which are
structurally distinct GPVI agonists – each caused rapid
activation of TC21 in human platelets, as early as 30 s
and persisting for up to 120 s (Fig. 5A). Thus, GPVI sig-
naling activates TC21 in platelets. Interestingly, TC21
was also activated rapidly upon platelet stimulation with
the PAR4 agonist AYPGKF, and the C-type lectin recep-
tor 2 (CLEC-2) agonist fucoidan (Fig. 5B).
Although signaling through multiple receptors activated
TC21 in platelets, the GPVI platelet response was selec-
tively impaired by TC21 deletion (Figs 2–4). As GPVI-
coupled Fc receptors harbor ITAM motifs that are
subject to tyrosine phosphorylation by SFKs, leading to
downstream signaling events [37,38], we investigated
whether TC21 activation by GPVI requires SFK activa-
tion, by using the SFK inhibitor PP2 and the control ana-
logue PP3. TC21 activation by CRP was completely
blocked in the presence of PP2, but not in the presence of
PP3, demonstrating that GPVI–FcRc-mediated TC21
activation requires SFK activity (Fig. 5C). We evaluated
CRP-induced TC21 activation in murine platelets, and
found similar activation profiles as in human platelets
(Fig. 5D, left panels; see also Fig. 5A). TC21 was
upstream of Syk activation induced by GPVI stimulation
(Fig. 4); however, TC21 could also be downstream of Syk
in a putative feedback loop. Therefore, we tested
CRP-induced TC21 activation under conditions of Syk
inhibition in WT murine platelets, and found that TC21
activation was unaffected by the Syk inhibitor OXSI-2
(Fig. 5D). Thus, TC21 is upstream of Syk in the GPVI
pathway and is not subject to negative feedback effects.
However, negative feedback downstream of Syk at later
time points could not be ruled out. On the basis of the
ability of TC21 to interact with ITAM receptors in other
cells, we considered whether TC21 may associate with the
GPVI–FcRc complex. GPVI was detected in TC21
immunoprecipitate fractions after CRP stimulation, indi-
cating that TC21 physically associates with the GPVI
complex upon receptor ligation (Fig. 5E). To investigate
further a role for TC21 in ITAM signaling in platelets,
we assessed TC21 activation following crosslinking of the
FccRIIa receptor, which is not expressed in murine plate-
lets. This ITAM receptor drives platelet signaling through
similar pathways as GPVI–FcRc, to affect aggregation
and thrombus formation [39,40]. Crosslinking of FccRIIa
in human platelets induced rapid activation of TC21
(Fig. 5F), suggesting a conserved ITAM-mediated mecha-
nism for TC21 activation in platelets.
TC21 is required for GPVI-induced Rap1b activation in
platelets
The RAS family small GTPase Rap1b plays an essential,
proximal role in the activation of aIIbb3 integrin in plate-
lets, by stimulating the recruitment of talin and cofactors
© 2018 International Society on Thrombosis and Haemostasis
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to the integrin tails [9]. As shown in Fig. 6, Rap1b activa-
tion induced by CRP was abolished in TC21-null plate-
lets, in contrast to robust Rap1b activation in WT
platelets. Thus, TC21 regulates GPVI-mediated integrin
activation and platelet activation through crosstalk signal-
ing required for activation of Rap1b.
CLEC-2-mediated platelet aggregation and downstream
signaling events in TC21-deficient platelets
To confirm that the block in integrin-mediated platelet
aggregation and secretion responses in TC21-null plate-
lets was GPVI-specific, we assessed aggregation and
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A
B
Fig. 4. Glycoprotein VI-mediated downstream signaling events are inhibited in TC21-null platelets. Washed platelets isolated from TC21-null
(TC21 knockout [KO]) and wild-type (WT) mice were stimulated for the indicated times with collagen-related peptide (CRP) (A) at the indi-
cated concentrations or (B) AYPGKF (100 lM) or 2MeSADP (25 nM) (60 s each), and lysed; lysates were immunoblotted with antibodies as
shown. Phosphoprotein/total protein ratios from six independent experiments are shown on the right in (A) for 2.5 lg mL1 CRP treatment.
Representative blots are shown. *P < 0.03. ERK, extracellular signal-regulated kinase; PLCc2, phospholipase Cc2; US, unstimulated.
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secretion in response to fucoidan, a sulfated polysaccha-
ride that stimulates platelet activation via Syk and
PLCc2, but through the CLEC-2 receptor, which har-
bors a hemi-ITAM motif [41], independently from the
GPVI–FcRc receptor complex at low concentrations
[42]. Fucoidan-induced platelet aggregation, aIIbb3 inte-
grin activation and a-granule secretion were normal in
both WT and TC21-null platelets (Fig. S1A–C). In
addition, fucoidan treatment induced Syk, PLCc2, AKT
and ERK1/2 phosphorylation in TC21-null platelets to
similar levels as in WT platelets (Fig. S1D). These
results indicate that TC21 is not important for platelet
aggregation or Syk and AKT phosphorylation down-
stream of the CLEC-2 receptor, and confirm that TC21
selectively functions downstream of the GPVI–FcRc
receptor complex in platelet activation.
Regulation of hemostasis and thrombosis in vitro and in vivo
by TC21
We next assessed the contributions of TC21 to thrombus
formation and stability in vitro and in vivo. We first inves-
tigated thrombus formation in vitro in whole blood flow-
ing over collagen-coated surfaces. As shown in Fig. 7A,
thrombus formation over collagen-coated surfaces was
significantly decreased in blood from TC21-null mice as
compared with that from WT mice. On the basis of these
results, we investigated putative roles for TC21 in
hemostasis and injury-induced thrombus formation and
stability in vivo. We first measured bleeding times follow-
ing tail clip, and found significantly increased bleeding
times in TC21 knockout mice (Fig. 7B). We measured
time to occlusion in the carotid artery, following 7.5%
FeCl3-induced injury for 90 s, in TC21-null and WT mice.
As shown in Fig. 8A, in vivo thrombosis at the site of
injury appeared to be slightly delayed, as observed by
increased time to occlusion, in TC21-null mice as com-
pared with WT mice. The average time to occlusion after
injury in TC21-deficient mice was 10.5 min, as compared
with 8 min in WT mice (Fig. 8B). However, this delay in
initial time to occlusion was not significant. In contrast,
embolization of the thrombi was observed in 64% of
TC21-null mice, as compared with 18% of WT mice
(n = 11), indicating unstable thrombi after arterial injury
in these mice (Fig. 8C). This result is consistent with pro-
longed bleeding in the tail clip thrombosis model in
TC21-null mice. Thus, the small GTPase TC21 is required
in platelets for rapid thrombus formation and mainte-
nance of thrombus stability in response to arterial injury
in mice.
TC21 effects on outside-in signaling in platelets
To obtain a broader picture of the contributions of TC21
to platelet responses, we analyzed platelet spreading on
immobilized fibrinogen and thrombin-induced clot retrac-
tion ex vivo. TC21-null platelets spread to a similar
degree as WT platelets (Fig. S2A). Similarly, thrombin-
induced clot retraction with TC21-deficient platelets pro-
ceeded at the same rate as with WT platelets ex vivo
(Fig. S2B). Thus, TC21 is not required for outside-in sig-
naling in platelets. Fibrin has also been shown to activate
GPVI by direct binding to the receptor [43,44]; however,
we did not observe differences in spreading on fibrin
between WT and TC21-null platelets, whereas TC21-null
platelets did not spread efficiently on collagen or CRP as
compared with WT platelets (Fig. S3), indicating that fib-
rin signaling in platelets does not require TC21.
Discussion
This study is the first to demonstrate a functional role for
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Fig. 5. TC21 activation by glycoprotein (GP) VI receptor agonists
downstream of Src kinases. (A, B) Washed platelets were stimulated
with 2.5 lg mL1 collagen-related peptide (CRP) or 75 ng mL1
convulxin (A), or 500 lM AYPGKF or 100 lg mL1 fucoidan (B),
and lysed; GTP-bound TC21 (upper panels) was then extracted from
platelet lysates (lower panels, total TC21) by the use of glutathione-
S-transferase–RAF-1-RBD coupled to gluthatione–sepharose beads.
(C) TC21 activation induced by 5 lg mL1 CRP for 60 s was evalu-
ated in the presence of 10 lM PP2 or PP3 as indicated. (D) Washed
platelets were incubated with 1 lM 2,3-dihydro-3-[(1-methyl-1H-
indol-3-yl) methylene]-2-oxo-1H-indole-5-sulfonamide (OXSI-2) or
dimethylsulfoxide (DMSO) vehicle for 5 min, stimulated with CRP
as shown, and then evaluated for total and GTP-bound TC21 as in
(A). (E) TC21 was immunoprecipitated from IgG–sepharose pre-
cleared lysates of GPVI-stimulated platelets, with 2 lg of anti-TC21
antibody. Washed immunoprecipitate fractions were subjected to
western blotting with antibodies against TC21 and GPVI as indi-
cated. (F) FccRIIa was crosslinked with 2.5 lg mL1 IV.3 antibod-
ies followed by 50 lg mL1 anti-mouse IgG (Fab02) for the
indicated times. GTP-bound, activated TC21 was precipitated from
platelet lysates and detected by western blotting as above. All data
are representative of three independent experiments each. a-ms, anti-
mouse; IP, immunoprecipitation; WCL, whole cell lysate.
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in platelet functional responses, hemostasis, and thrombo-
sis. TC21-deficient mice showed prolonged times to cessa-
tion of bleeding and a tendency to rebleed in a tail clip
hemostasis model, reduced platelet deposition on collagen
surfaces in whole blood under flow, and thrombus
embolization in the carotid artery following injury, indi-
cating a role for TC21 in both thrombus formation and
thrombus stability. Thrombus instability was attributable
to a defect in activation of aIIbb3 integrins in TC21-defi-
cient platelets downstream of impaired platelet signaling
responses. TC21-dependent platelet responses were selec-
tive for the GPVI–FcRc collagen receptor, and TC21 was
activated by GPVI stimulation upstream of Syk, pointing
to TC21 activation as a receptor-proximal event. TC21
was also required for downstream GPVI-mediated Rap1b
activation, demonstrating RAS GTPase crosstalk and a
RAS/Rap1b linkage in GPVI-mediated integrin activation
in platelets.
Prolonged bleeding in TC21 knockout mice in a tail
clip hemostasis model, and thrombus embolization in a
vascular thrombosis model, together suggest that TC21
plays an important role in the strength of platelet adhe-
sion and aggregation. This was supported by a defect in
TC21-deficient platelet thrombus formation in vitro in
blood flowing over collagen surfaces. In addition,
decreased platelet counts in TC21-deleted mice may also
contribute to impaired thrombosis and hemostasis. Many
hereditary platelet functional disorders, such as Bernard–
Soulier syndrome, von Willebrand disease, and Glanz-
mann’s thrombasthenia, result from compromised platelet
adhesive capacity, leading to complications of either
spontaneous bleeding or thrombosis defects [45–48]. Thus,
it is conceivable that somatic or inherited mutations in
TC21 may correlate with bleeding tendencies in humans,
but this merits further investigation.
The role of TC21 in platelet aggregation and thrombus
stability correlated with a role in activation of the aIIbb3
integrin fibrinogen receptor, indicating that TC21-mediated
thrombus stability is attributable to a requirement for
TC21 in platelet integrin activation. RAS family proteins,
including HRAS, RRAS1, and TC21, have been associated
with regulation of integrin activation in other contexts, and
these studies indicated a positive role for TC21 in integrin
activation [12,13,49]. However, these studies were focused
on ectopic expression of both integrins and RAS proteins
in heterologous cells. Thus, an integrin regulatory function
for RAS proteins had not previously been recognized in
platelets. Many studies have characterized upstream
CRP 2.5
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Fig. 6. TC21 is required for glycoprotein VI-mediated Rap1b
activation. GTP–Rap1b pulldown (upper panels) with glutathione-S-
transferase (GST)–RALGDS-RBD from lysates (total Rap1b, lower
panels) of wild-type (WT) or TC21-null (knockout [KO]) platelets
stimulated with collagen-related peptide (CRP) at the indicated
concentrations and for the indicated times. (A) Sixty seconds of
stimulation with 2.5 or 5 lg mL1 CRP. (B) Time course with







































Fig. 7. TC21 regulates thrombus formation over collagen surfaces
and in vivo hemostasis. (A) Representative images of thrombus for-
mation on collagen surfaces in blood from wild-type (WT) and
TC21-null (TC21 knockout [KO]) mice in a flow chamber. Percent-
ages of the imaging area covered by platelets are shown to the right,
+ standard error of the mean. *P < 0.05. (n = 5). Scale bar: 50 lm.
(B) Bleeding times following tail clip in WT and TC21-null mice.
*P < 0.002. (n = 20).
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regulators of RAS as playing roles in platelet integrin acti-
vation and function, including CALDAG-GEFs, which are
important for platelet adhesion and aggregation [50–54],
and an early report identified the GRB2 RAS activation
complex in these processes [55]. However, many of these
GEF proteins also stimulate activation of Rap1, which is
an integrin-proximal player essential for integrin activation
[9,56]. Hence, a direct role for proto-oncogenic RAS in pla-
telet integrin activation was not demonstrated. To our
knowledge, this study is the first to demonstrate a func-
tional role for a RAS protein (other than Rap1), i.e. TC21,
in the regulation of native integrins in platelets, which is
required for thrombus stability in vitro and in vivo.
TC21 signaling leading to integrin activation in plate-
lets was selectively downstream of the GPVI collagen
receptor, and TC21 appears to propagate signaling proxi-
mal to the receptor. TC21 was activated by GPVI
agonists (CRP and convulxin), indicating receptor-
mediated stimulation of a RasGEF promoting GTP load-
ing of TC21. The notion of TC21 as a receptor-proximal
signal transducer is consistent with our findings that
GPVI-induced TC21 activation required Src family kinase
activity, and was upstream of PLCc2, AKT, and ERK
[37,57–59]. TC21 was activated by GPVI stimulation
under conditions of Syk inhibition, placing TC21
upstream of Syk with minimal negative feedback signaling
from Syk to TC21. Moreover, TC21 associated with
GPVI following CRP agonist stimulation, indicating that
TC21 forms a molecular complex with GPVI upon liga-
tion. Thus, a GPVI ? Src ? TC21 ? Syk pathway reg-
ulates platelet activation. However, precisely how TC21
functions upstream of Syk in a Src-dependent manner
remains to be fully elucidated. Fibrin can activate GPVI





















































Fig. 8. Delay and instability of in vivo arterial thrombus formation in TC21-null mice. (A) Representative Doppler tracings of blood flow in
the carotid artery following FeCl3-induced injury in TC21-null (TC21 knockout [KO]) and wild-type (WT) mice. (B, C) Time to occlusion (B)
and stability of thrombus formation (C) as determined by lack of restored blood flow in Doppler tracings, n = 11 each. [Color figure can be
viewed at wileyonlinelibrary.com]
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responses of this interaction are poorly understood. We
did not observe fibrin-dependent spreading or clotting
defects in TC21-null platelets, suggesting that collagen-
mediated GPVI signaling through TC21 represents a dis-
tinct pathway from fibrin–GPVI signaling. As TC21 was
also activated by AYPGKF and fucoidan, it appears that
TC21 can be activated by multiple upstream signaling
pathways in platelets. Furthermore, TC21 was also acti-
vated in human platelets by crosslinking of the FccRIIa
receptor, which is similar to the GPVI/FcRc receptor, sig-
naling via ITAM motifs in the Fc chains. This pathway
has parallels with roles of TC21 in lymphocytes, where
TC21 associates with BCR (B cells) and TCR (T cells) via
interaction with ITAM motifs in each receptor, both of
which propagate signaling through Syk pathways
[21,33,60,61]. The GPVI–FcRc receptor complex also con-
tains ITAM motifs (in the FcRc chain) [38,62], suggesting
a possible conserved mechanism of TC21–ITAM motif
association in receptor signaling in hematopoietic cells.
Many RAS family GEFs stimulate RAS activation as a
result of recruitment to receptor phosphotyrosines, typi-
cally via adapter proteins – such a mechanism has been
shown to connect the cell adhesion receptor CEACAM3
with activation of RAC via direct binding of the RAC-
GEF VAV to phosphotyrosines in the receptor ITAM
[56,63], suggesting the potential for a conserved mecha-
nism of ITAM–GEF–RAS complex formation. However,
Syk is generally considered to bind directly to ITAM
motifs following phosphorylation by SFKs in many cells,
including platelets [64,65]; thus, the role of TC21 in medi-
ating this connection is unknown. Which GEFs mediate
GPVI-induced TC21 activation in platelets, and their
mechanism of action, also remain to be determined.
Our results demonstrate crosstalk between two RAS
GTPases, i.e. TC21/RRAS2 and Rap1b, in platelet signal-
ing and functional responses. TC21 was required for
GPVI-mediated Rap1b activation, which is a requisite
downstream signaling event leading to aIIbb3 integrin acti-
vation in platelets, as well as for activation of other inte-
grins through a common mechanism [9,51]. Thus, we
predict that, in the absence of TC21, talin recruitment to
integrin tails is compromised, preventing allosteric activa-
tion of the integrin ligand-binding domain [9,66,67]. The
molecular mechanisms by which TC21 regulates Rap1b
activation in platelets remain to be explored. However,
TC21 may be involved in integrin regulation in other con-
texts with varied physiological effects, e.g. Schwann cell
migration and tumor metastasis, which have been associ-
ated with increased TC21 activity [68–71].
Recent interest in hemostasis and thrombosis research
has been focused on identifying pharmacological targets
such as regulators of integrin activation, which strike a
balance between minimal bleeding events and mainte-
nance of hemostasis [72,73]. GPVI-deficient mice do not
show impaired hemostasis [74]; however, the hemostasis
defect observed in TC21-deficient mice may also be
attributable to lower platelet counts. Deficiency of TC21
is compatible with life, suggesting that targeting a TC21
pathway in platelets may have few unwanted effects.
Thus, the TC21 pathway may be a viable target for inter-
vention in pathological conditions driven by thrombus
instability, such as atherosclerosis and stroke.
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